 |
 |
Lintuzumab (SGN-33) is a humanized monoclonal antibody that targets the CD33 antigen, which is expressed on a number of hematologic malignancies, including acute myeloid leukemia and several myeloproliferative disorders.
For more detailed information about the clinical trials summarized below, click on the link to the trial listing at www.clinicaltrials.gov.
Randomized, double-blind, placebo-controlled trial evaluating low-dose cytarabine chemotherapy plus lintuzumab or placebo in previously untreated acute myeloid leukemia patients 60 years and older
Enrollment to this trial is complete.
Single-arm trial evaluating safety and activity of lintuzumab in combination with Velcade (bortezomib)
If you have questions about the lintuzumab clinical trials, please e-mail Seattle Genetics at clinicaltrials@seagen.com . Additional information about cancer, leukemia, MDS and participating in clinical trials can be found on the following web sites.